Eisai and Purdue Pharma collaborate on lemborexant

The US subsidiary of Japan’s Eisai (TYO: 4523) and privately-held US firm Purdue Pharma have entered into a worldwide collaboration agreement for the development and commercialization of Eisai's clinical candidate lemborexant (development code: E2006), a dual orexin receptor antagonist entering Phase III clinical development for the treatment of insomnia.

Under the terms of the agreement, Eisai and Purdue Pharma will share the costs of lemborexant global clinical studies. While the potential indication for the product candidate is for the treatment of insomnia, the companies may also seek to develop other indications in the future. In addition, the two companies will form a joint steering committee to manage development and pursue marketing authorizations for lemborexant worldwide.

Will co-promote, sharing costs and profits in USA and some other territories